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1. Introduction 
Hypertension and hypercholesterolemia are two major controllable risk factors of 
cardiovascular diseases (CVD), and have become the leading cause of morbidity and 
mortality worldwide, representing a continuous challenge to public health efforts (O'Donnell 
& Elosua, (2008). It has been established that high blood pressure combined with 
cholesterol levels over the desirable limits cause oxidative stress, impairment of 
endothelial function, vascular inflammatory responses and atherosclerosis (Ghiadoni, 
Taddei, & Virdis, 2012; Koh, Oh, & Quon, 2009). Besides pharmacological therapy, 
lifestyle and nutritional factors play a significant role in the prevention and treatment of 
pathologies as hypertension and hypercholesterolemia. The food industry, in association 
with research and public health institutions, has focused on the development of novel 
functional ingredients that aid in maintaining a normal blood pressure. These products 
could avoid the requirement to take antihypertensive drugs in borderline subjects 
(Hartmann & Meisel, 2007; Hernandez-Ledesma, Contreras, & Recio, 2011). 
Epidemiological studies suggest that the dietary intake of milk and dairy foods is related to 
a decreased risk of hypertension (Engberink et al., 2009). Besides their high mineral 
content (e.g., calcium, potassium and magnesium) that can lower blood pressure (van 
Mierlo et al., 2006), other milk components, such as proteins and their hydrolyzed 
products, have been also linked to the antihypertensive effect of dairy products (Svetkey et 
al., 1999; Toledo et al., 2009; Van Meijl & Mensink, 2011). In the last two decades, 
antihypertensive effects of some peptides generated from milk proteins have been 
evaluated in experimental animals (Ehlers et al., 2011; Jäkälä et al., 2009a; Jauhiainen et 
al., 2010; Martínez-Maqueda et al., 2012; Sánchez-Rivera et al., 2016; Tavares et al., 
2012). In this regard, several clinical trials have investigated the impact of lactotripeptides 
(isoleucine-proline-proline and valine-proline-proline) on blood pressure and vascular 
function, but only a few have examined the effects of other peptides from casein 
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hydrolyzates (Fekete, Givens, & Lovegrove, 2013; Pripp, 2008). Most of these peptides 
have demonstrated ACE-inhibitory activity, which is considered as one of the best 
strategies for hypertension management, nevertheless other mechanisms of action as 
antioxidant activity and opioid receptor agonist effect cannot be discarded (Nongonierma & 
FitzGerald, 2015).  
A hydrolyzate obtained by the action of pepsin on casein, containing the αs1-casein-
derived peptides RYLGY and AYFYPEL, has been patented and commercialized under 
the name of Lowpept® due to its antihypertensive properties demonstrated in both, 
spontaneously hypertensive rats (SHR) (Contreras et al, 2009 and 2011; Sánchez et al., 
2011) and hypertensive patients (Recio et al., 2011).  
On the other hand, several food compounds such as long chain omega-fatty acids and 
phytosterols can exert beneficial cardiovascular effects by lowering plasma total 
cholesterol (TC) and low density lipoprotein-cholesterol (LDLc) (Lees et al., 1977; Lopez-
Huertas, 2010; Marangoni & Andrea, 2010; Neil, Meijer, & Roe, 2001; Ras et al., 2016).  
The inhibition of cholesterol absorption in intestine is the main mechanism of action of 
phytosterols arising from chemical structure similarities between phytosterols and 
cholesterol (Calpe-Berdiel, Escolà-Gil, & Blanco-Vaca, 2009). The effects of phytosterols 
and phytosterol esters on vascular function and blood pressure are controversial and 
useful effects beyond lowering cholesterol have been suggested.  
Hypertension and high cholesterol levels are two risk factors present in a large part of the 
population susceptible of suffering coronary heart disease or stroke (Makovac, Thayer, & 
Ottaviani, 2016; Okopień, Bułdak, & Bołdys, 2016).  
Although the beneficial effects of the administration of phytosterols or milk peptides in 
cardiovascular health have been reported in different studies, few have investigated the 
co-administration (Ehlers et al., 2012; Turpeinen et al., 2009). Therefore, the aim of this 
study was to investigate if the addition of phytosterols to a casein hydrolyzate could have 
3 
 
beneficial synergistic effects on the management of hypertension and dyslipidemia. We 
assessed the effect of chronic treatment on blood pressure, vascular function, lipid profile 
and oxidative stress in hypercholesterolemic hypertensive rat. 
 
2. Materials and methods 
2.1. Experimental protocol 
All the experiments were performed according to the European Union guidelines for the 
ethical care and use of laboratory animals and the protocol was approved by the Bioethics 
Committee of University of Salamanca (Register Nº: 006Nº201400023665). Twenty-four 
male SHR 13-week old (Janvier Labs, Le Genest Saint Isle, France) were housed in boxes 
of 3-4 rats and maintained at a temperature of 23 ºC with 12 h light/dark cycles. Rats were 
fed on a solid standard diet (Global Diet 2014, Harlan Laboratories, Inc., Indianapolis, IN, 
USA) with ad libitum intake. 
After 14 days of adaptation, baseline blood pressure measurements were performed. The 
systolic blood pressure (SBP) was measured in awake rats using the CODA tail-cuff blood 
pressure system (Kent Scientific, Torrington, CT, USA). This system utilizes volume 
pressure recording sensor technology to measure the rat tail blood pressure. Before the 
measurements, the rats were kept at 30-35 ºC for 10-15 min to make detectable the 
pulsations of the tail artery. Arterial blood pressure measurements were carried out the 
same time of day (between 9 a.m. and 13 p.m.) in order to avoid the influence of the 
circadian cycle, and the values of SBP were obtained by estimating the average reading of 
8-10 measurements. Thereafter, based on the SBP values and body weights, animals 
were randomized into four groups (n=6). 
Group C: control SHR fed a standard diet. 
Group CH: hypercholesterolemic SHR, rats fed a high-cholesterol diet (standard diet 
supplemented with 1% cholesterol and 0.25% cholic acid). 
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Group CHL: hypercholesterolemic SHR treated with milk casein hydrolyzate (300 
mg/kg/day) incorporated in the chow.  
Group CHLP: hypercholesterolemic SHR treated with milk casein hydrolyzate (300 
mg/kg/day) and phytosterols (450 mg/kg/day) incorporated in the chow. 
The body weight (BW) was recorded weekly and blood pressure monitored every two 
weeks in all groups during the experimental period. Feed consumption was controlled 
every two days. 
At the end of the treatment (8 weeks), animals were anaesthetized with sodium 
pentobarbital (60 mg/kg BW, i.p.) and blood samples were collected. After that, tissues 
(heart, liver and aorta) were immediately harvested, placed in chilled Krebs solution 
(composition in mM: NaCl, 118; KCl, 4.7; CaCl2, 2.5; KH2PO4, 1.2; MgSO4, 1.2; NaHCO3, 
25 and glucose, 11, pH= 7.4) and appropriately processed for further studies. 
Blood samples were centrifuged at 350 g for 10 min, at 4 ºC, to obtain the plasma that was 
kept at -80 ºC until use. 
 
2.2. Left ventricular hypertrophy 
The atrium was removed from the heart and all the epicardial fat was scraped off. The right 
and the left ventricles were separated, regarding the interventricular septum as an integral 
part of the left ventricle, and this portion was weighed. The left ventricular hypertrophy 
(LVH) index was calculated using left ventricle weight/BW ratio. 
 
2.3. Morpho-histology of liver 
Isolated liver was washed with chilly Krebs solution and moisture was eliminated with filter 
paper. The liver hypertrophy (LH) index was determined using liver weight/BW ratio. 
A portion of large lobe of the liver was fixed in 10% formaldehyde for 72 hours. Fixed 
specimens were processed for paraffin embedding and 5 μm slices were stained with 
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hematoxylin-eosin. Histological sections were examined under an optical microscope and 
images were captured using a high-resolution digital camera (Olympus DP50, Tokyo, 
Japan). Size of hepatocytes was measured as an average of 10 hepatocytes taken from 
different zones of histological sections using ImageJ software (US National Institutes of 
Health, http://rsb.info.nih.gov/ij/). The hepatic steatosis was measured as percent area 
fraction of fat vacuole surrounding periportal area/total area of image. Adobe Photoshop 
(Adobe Photoshop® CS3, Microsoft) program was used to image analysis. 
 
2.4. Biochemical parameters measurement  
Triacylglycerols (TG), TC, high density lipoprotein-cholesterol (HDLc), alanine 
transaminase (ALT), aspartate transaminase (AST) levels were analyzed in plasma using 
reagent strips for quantitative measurement (SpotchemTM II, Arkray, Shiga, Japan) in a 
fully automatic biochemical analyzer (SpotchemTM EZ sp-4430, Arkray, Shiga, Japan). 
LDLc was calculated according to the formula: LDLc = TC-(HDLc+TG/5) and the 
atherogenic index (AI) was calculated as follows: AI = (TC-HDLc)/HDLc (Olmez et al., 
2015). 
 
2.5. Lipid peroxidation (TBARS) 
Lipid peroxidation, a marker of oxidative stress, was estimated in plasma by measurement 
of thiobarbituric acid-reactive substances (TBARS) previously described by Ohkawa, 
Ohishi and Yagi (1979) with minor modifications (Kassan et al., 2009). The results were 
expressed as concentration of TBARS (µM). 
 
2.6. Vascular reactivity measurements 
The thoracic aorta was carefully cleaned of fat and connective tissue and cut into rings (3 
mm length) that were placed between stainless steel hooks and set up in organ chambers 
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filled with 5 mL of Krebs solution, bubbled with carbogen (5% CO2, 95% O2) and kept at 37 
ºC. One of the hooks was fixed to the bath and the other connected to an isometric force 
transducer (UF1, Harvard apparatus Inc., Holliston, MA, USA). Force was recorded on a 
PC computer using Lab Chart version 3.4 software and a Power Lab/800 data acquisition 
system (AD Instruments, Oxford, UK). All rings were allowed to equilibrate for 1 h at a 
resting tension of 2 g. The Krebs solution was periodically changed and tension was reset 
during this period. Then, the vessels were exposed to phenylephrine (PE, 10−6 M) and the 
presence of functional endothelium was assessed by the ability of acetylcholine (ACh, 10−6 
M) to induce relaxation. After a washout period, cumulative concentration-response curves 
to PE (10−8 to 10−4M) were obtained. After pre-contraction with PE (10−6 M) and steady 
maximal contraction, cumulative concentration-response curves were obtained for ACh 
(10−8 to 10−4 M) or sodium nitroprusside (SNP, 10−9 to 10−4M). Each curve was obtained in 
different rings. 
Responses to PE were expressed as mg of contraction and responses to ACh and SNP as 
percentage of PE contraction.  
 
2.7. Detection of vascular superoxide anion  
Superoxide anion (O2•−) production was assessed by lucigenin-enhanced 
chemiluminescence assay. Briefly, segments of thoracic aorta were incubated in ROS 
phosphate buffer (composition in mM: KH2PO4, 50; EGTA, 1 and sucrose, 150, pH=7.4) 
supplemented with ammonium diethyldithiocarbamate (DDC, 10 mM), gassed with 
carbogen and maintained at 37°C for 15 min. Then, samples were transferred into tubes 
containing ROS phosphate buffer, DDC (10 mM), nicotinamide adenosine dinucleotide 
phosphate (NADPH, 10-4 M) and lucigenin (5 µM). Lucigenin chemiluminescence was 
recorded every 10 s for 5 min in a luminometer (LUMAT LB-9507, Berthold Technologies, 
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Bad Wildbad, Germany). Production of O2•− is expressed as relative luminescence units 
(RLU)/min/mg dry tissue. 
 
2.8. Compounds  
The milk casein hydrolyzate (Lowpept®) was prepared using commercial casein (Promilk 
85, Arras Cedex, France) that was hydrolyzed with food grade pepsin (Biocatalysts, 
Cardiff, UK), according to our previous paper (Contreras et al., 2011) and provided by 
Innaves S.A. (Vigo, Spain). 
Phytosterols were a concentrate of sterols containing mainly sterols from vegetable oils 
(Vitasterol® S-80 WDP (90%), provided by Vitae Caps S.A., Toledo, Spain). 
Cholesterol (PubChem CID: 5997); cholic acid (PubChem CID: 221493); acetylcholine 
chloride (PubChem CID: 6060); phenylephrine hydrochloride (PubChem CID: 5284443); 
sodium nitroprusside (PubChem CID: 11953895); thiobarbituric acid (PubChem CID: 
2723628), tricloroacetic acid (PubChem CID: 6421), ammonium diethyldithiocarbamate 
(PubChem CID: 88794), nicotinamide adenosine dinucleotide phosphate (PubChem CID: 
5884) and lucigenin (PubChem CID:65099) were purchased from Sigma-Aldrich (Madrid, 
Spain). All other chemicals were of analytical grade. Stock solutions of the drugs were 
prepared in ultrapure water, stored at -20 ºC and appropriate dilutions were made on the 
day of the experiments. 
 
2.9. Statistical analysis 
Data are expressed as means ± standard error of the mean (SEM). The cumulative 
concentration–response curves by ACh, SNP and PE were fitted to a logistic equation and 
the negative logarithm of the concentration producing half maximal effect (pD2) were 
calculated. Concentration-response curves comparison was performed according to the 
extra sum of squares F-test principle. The level of statistical significance was determined 
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by one-way analysis of variance (ANOVA) followed by Bonferroni’s test for multiple 
comparisons and two-way ANOVA for blood pressure data. Significance was accepted at 
P< 0.05. Fitting and statistical analysis were performed using GraphPad Prism® software 
(version 5.0; GraphPad Software, Inc., San Diego, CA, USA).  
 
3. Results 
3.1. Blood pressure 
Blood pressure values during the 8 weeks treatment are presented in Fig. 1. The induction 
of hypercholesterolemic status did not alter the SBP. The long-term treatment with milk 
casein hydrolyzate with or without phytosterols decreased the SBP of the hypertensive 
hypercholesterolemic rats from 4 weeks of treatment. During the treatment, there were no 
significant differences in SBP values between CHL and CHLP groups. 
 
3.2. Left ventricular hypertrophy  
There were no differences in the daily dietary intake or in the BW among groups (Table 1). 
Hypercholesterolemic diet did not modify the LVH index compared with control group, but 
both treatments resulting in a significant reduction of this parameter (Fig. 2). 
 
3.3. Morpho-histology of liver 
In contrast to the normal healthy appearance of the liver in the C group, the high-
cholesterol diet for 8 weeks induced an increase of liver size (Fig. 3). Liver from rats fed 
only with hypercholesterolemic diet exhibited increase in size hepatocytes (CH=896±65 
versus C=430±17 µm2, p<0.05), massive fatty changes and severe steatosis, as it is 
shown in histological sections (Fig. 4). Treatment with milk casein hydrolyzate failed to 
reduce hypertrophy (CHL=855±27 µm2) and steatosis, however phytosterols addition 
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reversed the hepatocytes to normal values (CHLP=569±74 µm2) and the hepatic steatosis 
was remarkably lower, and the hepatic cells exhibited normal histology. 
 
3.4. Biochemical parameters and lipid peroxidation assessment 
Table 1 summarizes the parameters measured in plasma in order to evaluate the changes 
on lipid profile, transaminases and the extent of lipid peroxidation between the different 
groups. The hypercholesterolemic diet (group CH) dramatically increased the plasmatic 
levels of TC, LDLc and AI, a slight decrease of HDLc was also measured and no 
significant changes were observed in TG levels, which demonstrated the hyperlipidemic 
model was successfully established. Even though the oral administration of milk casein 
hydrolyzate during 8 weeks did not cause any effect in preventing alterations related to the 
hypercholesterolemic status, the addition of phytosterols resulted in a significantly 
recovery of TC, LDLc levels and AI.  
The levels of enzymes AST and ALT were greater in CH group compared with the C 
group, indicating that lipid accumulation was harmful to the liver. Treatment with milk 
casein hydrolyzate produced a significant reduction in ALT, and a slight attenuation in AST 
not statistically significant compared to the hypercholesterolemic SHR group untreated. 
The addition of phytosterols to casein hydrolyzate produced a greater effect at the level of 
these hepatic enzymes, obtaining similar values to the control SHR group. 
Moreover, rats receiving the hypercholesterolemic diet showed a remarkable increase of 
lipid peroxidation products in plasma. Although the treatment with milk casein hydrolyzate 
slightly attenuated lipid peroxidation levels, only the incorporation of phytosterols to the 
diet was able to get a significant effect respect to CH group.  
 
3.5. Vascular reactivity  
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Endothelium-dependent relaxation induced by ACh showed no difference between C 
(Emax=42.2±2.1% and pD2=7.5±0.2) and CH groups (Emax=45.8±2.0% and 
pD2=7.5±0.1), but the groups treated with milk casein hydrolyzate regardless of the 
presence (Emax=57.4±4.1% and pD2=7.7±0.3) or absence (Emax=57.0±3.7% and 
pD2=7.5±0.2) of phytosterols showed significantly greater relaxation to ACh (Fig. 5a). 
SNP-induced endothelium-independent relaxation reached proximately 100% in all groups. 
The sensibility to this agent was higher in vessels of treated animals with milk casein 
hydrolyzate (pD2=7.8±0.1) or milk casein hydrolyzate plus phytosterols (pD2=7.9±0.1) than 
in CH group and not differences between C and CH groups were observed (pD2=7.4±0.1 
and pD2=7.6±0.1, respectively) (Fig. 5b).  
Phenylephrine-induced contractile responses in aortic rings from different groups are 
shown in Fig. 6. Rings from rats fed with hypercholesterolemic diet did not modify the 
response to phenylephrine (C group, Emax=2104±105 mg and CH group, 
Emax=2343±206 mg), and treatment with milk casein hydrolyzate achieved a significantly 
reduction of contractile response (Emax=1495±142 mg). Additional treatment with 
phytosterols did not modify this response (Emax=1707±219 mg). 
 
3.6. Vascular superoxide anion 
The O2•− production stimulated by NADPH in aortic rings is shown in Fig. 7. 
Hypercholesterolemic diet caused an increase of this free radical. The treated groups with 
casein hydrolyzate shown statistical significant reduction in generation of O2•−. Interesting, 
these levels were lower in group receiving casein hydrolyzate with phytosterols.  
 
4. Discussion 
This investigation has been conducted in SHR with experimentally induced 
hypercholesterolemia. SHR is a phenotype-driven rat experimental model in which 
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hypertension is associated with cardiac hypertrophy, endothelial dysfunction and oxidative 
stress; and extensively used in research since resembles human hypertension (Lerman et 
al., 2005). The diet-induced hypercholesterolemia is used to promote alterations on lipid 
profile, redox balance and liver damage (Abreu et al., 2014; Deepa & Varalakshmi, 2003). 
Hypertension and hypercholesterolemia are two major risk factors of cardiovascular 
diseases and great efforts are being made to control them. 
The long-term effects of a milk casein hydrolyzate containing active peptides or fortified 
with phytosterols were investigated on blood pressure, morphological and histological 
alterations of organs, vascular function, lipid profile and oxidative stress. Phytosterols were 
included in the study to find out a possible additional effect on the aforementioned 
variables.  
Our previous studies showed that long-term treatment with milk casein hydrolyzate 
containing the αs1-casein derived peptides, RYLGY and AYFYPEL, attenuated the 
development of hypertension, exerted a cardiovascular protective effect in SHR (Sánchez 
et al., 2011) and decreased blood pressure (about 12 mmHg) in hypertensive subjects 
(Recio et al., 2011). Recently, bioactive milk peptides have gained interest because of 
their notable antihypertensive, antioxidant, anti-inflammatory, and hypocholesterolemic 
effects (Hsieh et al., 2015). In the current study, the casein hydrolyzate decreased SBP in 
hypercholesterolemic SHR, but any additional reduction on blood pressure was observed 
after supplementation with phytosterols. Therefore, we assume that phytosterols do not 
contribute to the antihypertensive effect. In this sense, Kim et al. (2008) also reported no 
effects on blood pressure in conscious SHR fed with a diet fortified with phytosterol esters 
for 9 weeks and other studies in human pointed at the ineffectiveness of phytosterols or 
stanols to reduce blood pressure (Hallikainen et al., 2006; Tapola et al., 2004).  
Hypertension is a major cause of cardiac hypertrophy, which frequently leads to heart 
failure (Gradman & Alfayoumi, 2006). In concordance with our results on blood pressure 
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above mentioned, additional alterations in LVH caused by hypercholesterolemic diet were 
not observed, however treatment with milk casein hydrolyzate regardless of the presence 
of phytosterols decreased the hypertrophic index. 
It is known that SHR from 10 to 12 week-old, show marked endothelial dysfunction 
(Bernatova et al., 2009). As expected, our results on vascular reactivity in aortic rings 
showed impaired endothelial function in control SHR fed a standard diet while the 
induction of a hypercholesterolemic status did not aggravate vascular dysfunction. 
Lorkowska et al. (2006) reported similar results, justified by a modest lipid accumulation in 
the vascular wall insufficient to induce alterations in vascular function. 
We had previously reported that relaxation to ACh on aortic and mesenteric rings from 
SHR improved after 6-week treatment with the casein hydrolyzate and contraction to 
phenylephrine was lower (Sánchez et al. 2011). Here, using aorta from 
hypercholesterolemic SHR we corroborated the benefits of casein hydrolyzate on 
endothelial function and evidenced the ineffectiveness of supplementation with 
phytosterols. 
In agreement with our results, other researchers also observed no additional effects on 
vasorelaxation response in arteries from SHR treated with fermented milk products 
containing tripeptides when plant sterols were co-administered (Ehlers et al., 2011 and 
2012; Jäkälä et al., 2009b).It has to be noted that, both, milk casein hydrolyzate alone or 
combined with phytosterols increased the sensitivity of the aortic rings to the endothelium-
independent vasodilator SNP. However, previous reports had not shown differences on 
response to SNP between control animals and treated with milk casein derived products 
(Jäkälä et al., 2009a and 2009b; Sánchez et al., 2011). It can be hypothesized that this 
discrepancy could be due to the use of older rats in the present study, in which arterial 
dysfunction might have further progressed, and thus, the positive effect of milk casein 
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hydrolysate on smooth muscle cells could be more pronounced; in addition to a longer 
treatment period in comparison with previous studies. 
The effect of diets supplemented with phytosterols on vascular function have not received 
much attention, and it is difficult to precise its effect, because they are often incorporated 
into products together with other bioactive components. In this regard, Hallikainen et al. 
(2006) administered either plant sterols or stanols esters to hypercholesterolemic subjects 
for 10 weeks, and this treatment did not affect the dilatation of the brachial artery. In 
another study, plant sterols consumption for 2 years did not significantly improve carotid 
artery compliance in healthy subjects (Raitakari, Salo, & Ahotupa, 2008). A study with 
male C57/Bl6 mice fed with 2% plant sterol ester-supplemented diet for 4 weeks showed 
that the endothelium-dependent relaxation of aortic rings was slightly impaired in 
comparison to the controls (Weingartner et al., 2008). 
Elevated plasmatic levels of TC and LDLc along with low HDLc are often associated with 
premature atherosclerosis and CVD (Assmann & Gotto, 2004). High cholesterol diet raises 
plasma LDLc levels and oxidative stress, both result in the production of oxidized LDLc 
and thereby increases atherosclerotic plaque formation. The cardioprotective effects of 
HDLc are associated to its role in reversing cholesterol transport, its effects on endothelial 
cells, and its antioxidant activity (Akalin-Çiftçi et al., 2015).As expected, our results in 
hypercholesterolemic untreated rats reproduced this pattern with lower HDLc and higher 
TC and LDLc levels than those from animals receiving standard diet, which led to an 
increased AI. Morphological and biochemical studies also revealed liver injury 
characterized by hepatomegaly and high levels of AST and ALT enzymes. Moreover, 
histology revealed large size hepatocytes and steatosis in CH group. Similar results have 
been reported by others researchers in Goto-Kakizaki and Wistar rats (Kengkoom et 
al.,2013) and Fischer rats (Abreu et al., 2014) after hypercholesterolemic diets. Treatment 
with casein hydrolyzate alone failed to revert most of the alterations previously indicated, 
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thus it seems that phytosterols were solely responsible for improving the lipidic profile and 
hepatic damage.  
Both hypertension and hypercholesterolemia are associated with a large increase in 
reactive oxygen species, a situation which finally ends with oxidative stress that promotes 
cell growth, inflammation, extracellular matrix deposition, etc; resulting in endothelial 
dysfunction, cardiac hypertrophy, lipid peroxidation, etc. (Ellulu et al., 2016; Montezano & 
Touyz, 2014). To demonstrate any implication of the treatments on oxidative stress we 
measured the TBARS and O2•−. In this sense, it is well known that these biomarkers are 
higher in SHR than in normotensive rats. We found that both were significantly increased 
when SHR were fed with the hypercholesterolemic diet. Unlike results previously 
discussed, the co-administration of phytosterols was effective, since the reduction of lipid 
peroxidation in the groups of animals treated with milk casein hydrolysate, respect to CH 
group, achieved statistical significance with the addition of phytosterols. The determination 
of O2•− supported the antioxidant action of the hydrolyzate and the synergistic effect of 
phytosterols. It is worth noting that, in addition to the antihypertensive effect, in vitro 
scavenger activity has been already reported for peptides from this casein hydrolyzate 
(Contreras et al., 2009) and otherwise, phytosterols have displayed an important 
hypolipidemic activity (Neil, Meijer, & Roe, 2001; Marangoni & Andrea, 2010). Therefore, 
the joint administration of both compounds would be suitable when hypertension and 
hypercholesterolemia coexist. 
 
5. Conclusion  
In hypercholesterolemic hypertensive rats, chronic treatment with milk casein hydrolyzate 
improved the parameters related to the hypertensive process, while the incorporation of 
phytosterols prevented the alterations caused by the hipercholesterolemia. Just the 
increase in oxidative stress, present in hypertension and hipercholesterolemia, showed a 
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greater reduction after co-administration. Therefore, the administration of the casein 
hydrolyzate fortified with phytosterols would be indicated when both disorders occur 
together. 
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FIGURES CAPTIONS 
 
Figure 1. Systolic blood pressure (SBP) in control SHR (C), untreated 
hypercholesterolemic SHR (CH), treated hypercholesterolemic SHR with milk casein 
hydrolyzate (CHL) or milk casein hydrolyzate plus phytosterols (CHLP). 
Values are expressed as mean ± SEM of 6 rats.  
**P<0.01, ***P<0.001 vs. CH. 
 
Figure 2. Left ventricular hypertrophy (LVH) index at the end of study (8 weeks) in control 
SHR (C), untreated hypercholesterolemic SHR (CH), treated hypercholesterolemic SHR 
with milk casein hydrolyzate (CHL) or milk casein hydrolyzate plus phytosterols (CHLP).  
Values are expressed as mean ± SEM of 6 rats.  
**P<0.01, ***P<0.001 vs. CH. 
 
Figure 3. Liver hypertrophy (LH) index at the end of study (8 weeks) in control SHR (C), 
untreated hypercholesterolemic SHR (CH), treated hypercholesterolemic SHR with milk 
casein hydrolyzate (CHL) or milk casein hydrolyzate plus phytosterols (CHLP).  
Values are expressed as mean ± SEM of 6 rats.  
###P<0.001 vs. C; *P<0.05 vs. CH; +P<0.05 vs. CHL. 
 
Figure 4. Histological sections of liver (×20) and hepatic steatosis area (%) at the end of 
study (8 weeks) in control SHR (C), untreated hypercholesterolemic SHR (CH), treated 
hypercholesterolemic SHR with milk casein hydrolyzate (CHL) or milk casein hydrolyzed 
plus phytosterols (CHLP).  
Values are expressed as mean ± SEM of 6 rats.  
###P<0.001 vs. C; *** P<0.001 vs. CH; +++ P<0.001 vs. CHL. 
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Figure 5. Cumulative concentration–response curves to acetylcholine (a) and sodium 
nitroprusside (b) in pre-constricted aortic rings from control SHR (C), untreated 
hypercholesterolemic SHR (CH), treated hypercholesterolemic SHR with milk casein 
hydrolyzate (CHL) or milk casein hydrolyzed plus phytosterols (CHLP).  
Values are expressed as mean ± SEM of 6 rats. 
 **P<0.01, ***P<0.001 vs. CH. 
 
Figure 6. Cumulative concentration–response curves to phenylephrine in aortic rings from 
control SHR (C), untreated hypercholesterolemic SHR (CH), treated hypercholesterolemic 
SHR with milk casein hydrolyzate (CHL) or milk casein hydrolyzed plus phytosterols 
(CHLP).  
Values are expressed as mean ± SEM of 6 rats.  
*P<0.05, **P<0.01 vs. CH. 
 
Figure 7. Vascular superoxide anion (O2•−) generation stimulated by NADPH addition in 
aortic rings from control SHR (C), untreated hypercholesterolemic SHR (CH), treated 
hypercholesterolemic SHR  with milk casein hydrolyzate (CHL) or milk casein hydrolyzed 
plus phytosterols (CHLP).  
Values are expressed as mean ± SEM of 6 rats.  
###P<0.001 vs. C; * P<0.05, *** P<0.001 vs. CH. 
 
Table 1. 
 
 
Table 1. Daily intake of feed, water consumption, weight gain, lipid profile, 
atherogenic index (AI), transaminases (AST, ALT) and lipid peroxidation 
(TBARS) at the end of experiment (8 weeks) in control SHR (C), untreated 
hypercholesterolemic SHR (CH), treated hypercholesterolemic SHR with milk 
casein hydrolyzate (CHL) or milk casein hydrolyzate plus phytosterols (CHLP).  
 
TC, total Cholesterol; TG, Triacylglycerols; LDLc, low density lipoprotein-
cholesterol; HDLc, high density lipoprotein-cholesterol; AST, aspartate 
transaminase; ALT, alanine transaminase. 
Values are expressed as mean ± SEM of 6 rats.  
#P<0.05, ###P<0.001 vs. C; *P<0.05, **P<0.01 vs. CH; ++P<0.01, +++P<0.001 vs. 
CHL. 
 
 
C CH CHL CHLP 
Feed intake (g/day) 23.1 ± 0.2 22.8 ± 0.3 22.7 ± 0.2 23.3 ± 0.2 
Water consumption (mL/day) 35.4 ± 1.2 36.2 ± 0.9 37.1 ± 1.1 36.7 ± 0.8 
Weight gain (g/8 weeks) 93.8 ± 8.4 89.0 ± 4.6 102.8 ± 5.3 109.4 ± 4.3 
TC (mg/dL) 84.5 ± 6.8 145.3 ± 7.6### 147.7 ± 10.4 94.5 ± 7.0**, +++ 
TG (mg/dL) 97.0 ± 19.3 118.7 ± 16.3 81.2 ± 9.6 98.7 ± 7.0 
LDLc (mg/dL) 36.5 ± 5.2 93.8 ± 9.0### 103.1 ± 9.8 42.6 ± 7.4**, +++ 
HDLc (mg/dL) 38.0 ± 3.7 27.8 ± 1.2# 28.3 ± 2.8 32.1 ± 1.5 
AI 1.3 ± 0.3 4.3 ± 0.4### 4.5 ± 0.7 2.0 ± 0.2**, ++ 
AST (IU/L) 42.2 ± 4.3 103.8 ± 15.6## 86.2 ± 14.7 48.6 ± 2.5* 
ALT (IU/L) 24.8 ± 1.6 69.6 ± 4.0### 31.4 ± 2.7*** 27.4 ± 3.8*** 
TBARS (µM) 2.8 ± 0.1 4.3 ± 0.4### 3.8 ± 0.2 3.2 ± 0.2* 
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